当前位置:首页 - 行情中心 - 东北制药(000597) - 财务分析 - 现金流量表

东北制药

(000597)

  

流通市值:80.33亿  总市值:81.34亿
流通股本:14.09亿   总股本:14.27亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金3,606,849,971.621,512,950,908.837,259,519,087.185,877,044,727.61
  收到的税费返还7,043,642.152,458,095.1518,601,190.8316,459,661.05
  收到其他与经营活动有关的现金119,775,485.0975,954,033.83312,470,397.65223,851,078.74
  经营活动现金流入小计3,733,669,098.861,591,363,037.817,590,590,675.666,117,355,467.4
  购买商品、接受劳务支付的现金2,143,306,384.51869,794,866.483,877,759,625.283,534,534,806.96
  支付给职工以及为职工支付的现金570,123,111.4336,937,014.141,003,139,832.02791,015,975.08
  支付的各项税费225,562,573.46123,779,080.87510,220,933.27401,237,250.78
  支付其他与经营活动有关的现金689,562,361.37291,709,382.381,440,709,163.88962,001,684.7
  经营活动现金流出小计3,628,554,430.741,622,220,343.876,831,829,554.455,688,789,717.52
  经营活动产生的现金流量净额105,114,668.12-30,857,306.06758,761,121.21428,565,749.88
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额34,604.831,219.82,702,990368,990
  投资活动现金流入小计34,604.831,219.82,702,990368,990
  购建固定资产、无形资产和其他长期资产支付的现金50,108,364.626,796,702.93159,425,992.57136,098,061.37
  取得子公司及其他营业单位支付的现金--127,243,511.2-
  投资活动现金流出小计50,108,364.626,796,702.93286,669,503.77136,098,061.37
  投资活动产生的现金流量净额-50,073,759.8-26,765,483.13-283,966,513.77-135,729,071.37
三、筹资活动产生的现金流量:
  取得借款收到的现金1,818,800,0001,440,000,0001,772,200,0001,462,200,000
  收到其他与筹资活动有关的现金4,912,421,414.51,813,729,501.8213,246,058,631.889,542,207,687.5
  筹资活动现金流入小计6,731,221,414.53,253,729,501.8215,018,258,631.8811,004,407,687.5
  偿还债务支付的现金1,571,450,000991,850,0002,447,629,999.991,536,029,999.99
  分配股利、利润或偿付利息支付的现金191,008,884.8130,896,025.49206,138,041.64194,315,937.72
  其中:子公司支付给少数股东的股利、利润---45,491.5
  支付其他与筹资活动有关的现金4,951,877,230.662,294,634,183.5513,517,928,475.79,659,924,804.65
  筹资活动现金流出小计6,714,336,115.473,317,380,209.0416,171,696,517.3311,390,270,742.36
  筹资活动产生的现金流量净额16,885,299.03-63,650,707.22-1,153,437,885.45-385,863,054.86
四、汇率变动对现金及现金等价物的影响-4,941,908.96-1,595,224.129,678,799.74-8,467,441.96
五、现金及现金等价物净增加额66,984,298.39-122,868,720.53-668,964,478.27-101,493,818.31
  加:期初现金及现金等价物余额2,097,991,603.942,097,991,603.942,766,956,082.212,766,956,082.21
  期末现金及现金等价物余额2,164,975,902.331,975,122,883.412,097,991,603.942,665,462,263.9
补充资料:
  净利润124,262,718.49-423,282,321.89-
  资产减值准备43,517,471.18-123,022,277.68-
  固定资产和投资性房地产折旧247,650,398.12-502,912,009.99-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧247,650,398.12-502,912,009.99-
  无形资产摊销26,937,331.52-46,589,093.3-
  长期待摊费用摊销3,930,384.7-952,215.03-
  处置固定资产、无形资产和其他长期资产的损失-181,512.23--6,192,436.61-
  财务费用29,254,824.43-95,570,177.45-
  投资损失-2,871,681.33--5,160,420.26-
  递延所得税-3,952,205.1-87,214,637.59-
  其中:递延所得税资产减少-3,314,225.17--3,310,209.65-
    递延所得税负债增加-637,979.93-90,524,847.24-
  存货的减少10,293,862.77-57,138,619.93-
  经营性应收项目的减少-214,656,097.26--82,526,143.81-
  经营性应付项目的增加-172,746,692.92--528,694,554.68-
  其他-143,293.9-22,184,004.71-
  不涉及现金收支的投资和筹资活动金额其他项目6,740,766.46-43,755,259.14-
  现金的期末余额2,164,975,902.33-2,097,991,603.94-
  减:现金的期初余额2,097,991,603.94-2,766,956,082.21-
  现金及现金等价物的净增加额66,984,298.39--668,964,478.27-
公告日期2025-08-272025-04-292025-04-032024-10-24
审计意见(境内)标准无保留意见
TOP↑